Extracellular Signal-Regulated Kinase 1/2 Regulates Mouse Kidney Injury Molecule-1 Expression Physiologically and Following Ischemic and Septic Renal Injury

Justin B. Collier and Rick G. Schnellmann

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA (J.B.C.); Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ (R.G.S.)

Current Address: University of Arizona, Drachman Hall, 1295 N. Martin Ave., POB 210202, Tucson, AZ 85721-02023. (J.B.C., R.G.S.)
Running Title Page

ERK1/2 Regulates KIM-1 in AKI

Corresponding Author: Rick G. Schnellmann, University of Arizona, Drachman Hall, 1295 N. Martin Ave., POB 210202, Tucson, AZ 85721-02023. Email: schnell@pharmacy.arizona.edu (R.G.S.)

Number of text pages: 27 of 33

Number of tables: 0

Number of figures: 6 + 1 Visual Abstract

Number of references: 42

Words in Abstract: 205

Words in Introduction: 539

Words in Discussion: 1061

Abbreviations: AKI, acute kidney injury; Chk1, checkpoint kinase 1; CLP, cecal ligation and puncture; ERK1/2, extracellular signal-regulated kinase 1/2; IR, ischemia reperfusion; KIM-1, kidney injury molecule-1; KO, knockout; LPS, lipopolysaccharide; MEK, mitogen-activated protein kinase kinase; SCr, serum creatinine; STAT3, signal transducer and activator of transcription 3; TK, transgenic kidney proximal tubule cell; TLR4, Toll-like receptor 4

Recommended Section: Cellular and Molecular
Abstract
The upregulation of kidney injury molecule-1 (KIM-1) has been extensively studied in various renal diseases and following acute injury; however, the initial mechanisms controlling KIM-1 expression remain limited. In this study, KIM-1 expression was examined in mouse renal cell cultures and in two different models of acute kidney injury (AKI), ischemia-reperfusion (IR) and lipopolysaccharide (LPS)-induced sepsis. KIM-1 mRNA increased in both AKI models and pharmacological inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling attenuated injury induced KIM-1 expression in the renal cortex. Toll-like receptor 4 knockout (TLR4KO) mice exhibited reduced ERK1/2 phosphorylation and attenuated KIM-1 mRNA after LPS exposure. TLR4KO mice were not protected from IR-induced ERK1/2 phosphorylation and upregulation of KIM-1 mRNA. Following renal IR injury, phosphorylation of signal transducer and activator of transcription-3 (STAT3) at S727 and Y705 increased downstream of ERK1/2 activation. Because phosphorylated STAT3 is a transcriptional upregulator of KIM-1 and inhibition of ERK1/2 attenuated increases in STAT3 phosphorylation, we suggest an ERK1/2-STAT3-KIM-1 pathway following renal injury. Finally, ERK1/2 inhibition in naïve mice decreased KIM-1 mRNA and nuclear STAT3 phosphorylation in the cortex, indicating homeostatic regulation of KIM-1. These findings reveal renal ERK1/2 as an important initial regulator of KIM-1 expression in IR and septic AKI and at a physiological level.
Visual Abstract

**Visual Abstract.** Proposed mechanism of IR, LPS, and ROS-induced renal damage that initiates ERK1/2 and STAT3 phosphorylation. STAT3 then binds to the KIM-1 promoter and increases KIM-1 mRNA. By preventing ERK1/2 phosphorylation following renal injury, STAT3 phosphorylation is decreased, leading to less phosphorylated STAT3 within the nucleus, and subsequently less KIM-1 mRNA increases post injury.
Introduction

KIM-1 is a type I transmembrane glycoprotein that is rapidly upregulated at the gene and protein level following various types of injury to the kidney (Ichimura et al., 1998; Amin et al., 2004; Vaidya et al., 2010). For example, KIM-1 is increased in IR, cisplatin, sepsis, folic acid, aristolochic acid and gentamicin-induced injuries, as well as occurring in disease states, such as renal cell carcinoma, polycystic kidney disease, hyperoxaluria, and hypertension (Han et al., 2005; Ichimura and Mou, 2008; Khandrika et al., 2012; Tian et al., 2017).

The ectodomain, which contains an Ig-like domain and a glycosylated mucin domain, is cleaved by the metalloproteinase ADAM17 at the cellular membrane (Ichimura et al., 1998; Bailly et al., 2002; Gandhi et al., 2014). Membrane bound KIM-1 and cleaved KIM-1 increase with worsening renal injury (Zhang et al., 2007). KIM-1 is located on the apical surface of renal proximal tubule epithelial cells and recognizes phosphatidylserine and oxidized lipoprotein epitopes on the surface of apoptotic bodies (Ichimura et al., 2008).

The extracellular signal-regulated kinase 1/2 (ERK1/2) is a mitogen-activated protein kinase (MAPK) that is phosphorylated rapidly following renal injury (Masaki et al., 2003; Arany et al., 2004; Masaki et al., 2004). We previously demonstrated ERK1/2 phosphorylation is elevated 3 hr post IR injury and 1 hr post LPS induced AKI (Smith et al., 2015; Collier et al., 2016). Further exploration of the ERK1/2 pathway was performed utilizing a specific MEK1/2 inhibitor, trametinib, which inhibits the increase in ERK1/2 phosphorylation, since MEK1/2 is directly upstream of ERK1/2 (Gilmartin et al., 2011; Yamaguchi et al., 2011). Interestingly, inhibiting LPS induced ERK1/2 phosphorylation prevented KIM-1 mRNA upregulation at 3 and 18 hr post LPS administration. Smith et al. confirmed ERK1/2 inhibition attenuates the upregulation of KIM-1 mRNA following injury utilizing trametinib treatment 6 hr post cecal ligation and puncture (CLP) surgery, a model of sepsis (Smith et al., 2016).
ERK1/2 and KIM-1 were studied in vitro using a porcine kidney epithelial cell line, LLC-PK₁, transfected with human KIM-1 (Zhang and Cai, 2016). KIM-1 protein promoted cell migration and proliferation through activation of the ERK1/2 pathway, and inhibiting ERK1/2 attenuated these processes. Recently, KIM-1 was shown to modulate macrophages by promoting an M1 phenotype and macrophage migration by MAPK pathways, including ERK, p38, and JNK (Tian et al., 2017). It is clear that ERK1/2 and KIM-1 are activated and upregulated shortly after kidney injury, however a direct connection between ERK1/2 and KIM-1 has received limited study.

Ajay et al. used a combination of bioinformatics, in vitro, and in vivo experiments to determine that signal transducer and activator of transcription-3 (STAT3) phosphorylation at serine 727 (S727) and tyrosine 705 (Y705) increases KIM-1 transcription by binding to the KIM-1 specific promoter (Ajay et al., 2014). Checkpoint kinase 1 (Chk1) was upregulated following IR injury due to DNA damage which phosphorylated STAT3 and subsequently regulated KIM-1 expression (Ajay et al., 2014). Interestingly, ERK2 was the most enriched upstream kinase identified that was associated with the highest upregulated transcription factors following IR injury (Berger et al., 2007; Lachmann and Ma'ayan, 2009; Ajay et al., 2014). Given this information and our previous data demonstrating ERK1/2 is rapidly phosphorylated post IR injury, we hypothesized early ERK1/2 activation following injury preferentially regulates KIM-1 expression.
Materials and Methods

In Vitro. A transgenic kidney proximal tubule (TK) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss, was used in all in vitro experiments (MacKay et al., 1988; Ernest and Bello-Reuss, 1995). TK cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red, or sodium pyruvate) supplemented with 5mM glucose, 10% FBS, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 ug/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM) were added to fresh culture medium. 90-95% confluent TK cells were used for all experiments, and FBS was removed from culture media 24 hr before experimentation. TK cell monolayers were treated HU (Fisher Scientific- AC151680050), TBHP (Sigma- #458139), and H2O2 (Sigma- H1009) or vehicle (DMSO-Sigma) for time points indicated. Different TK cell passages used on different days represent the “N” value for the in vitro studies.

Naïve and AKI Studies. Trametinib (GSK1120212, (Gilmartin et al., 2011)) was purchased from Selleckchem Chemicals (Houston, TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) were acquired from Charles River Laboratories (Frederick, MD) and received an injection of trametinib (1 mg/kg i.p.) or vehicle control (NEOBEE M-5 – Fisher Scientific). Four hours after injection kidneys were collected and flash frozen in liquid nitrogen for further analysis.

For IR AKI, mice were assigned to 3 groups: 1) Sham, 2) IR + Vehicle, 3) IR + Trametinib. Vehicle or trametinib were administered i.p 1 hr before surgery. For TLR4KO IR AKI mice were assigned to 4 groups: 1) WT sham, 2) TLR4KO SHAM, 3) WT IR, 4) TLR4KO IR. IR grouped mice were subjected to IR surgery by bilateral renal pedicle clamping for 18.5 min as described previously (Funk and Schnellmann, 2012). Briefly, the renal artery and vein were isolated and blood flow was occluded with a vascular clamp for 18.5 min while maintaining a constant body temperature of 36~37°C. Sham mice were treated exactly the same as IR mice, except without the clamping of the renal pedicles. Mice were
euthanized at 3 or 24 h after surgery, and blood and kidneys (flash frozen in liquid nitrogen) were collected for analysis.

For LPS model of sepsis, eight week old male C57BL/6 mice (20–25 g) were given an i.p injection of 10 mg/kg LPS derived from Escherichia coli serotype O111:B4 (Sigma-Aldrich, St. Louis, MO). Control mice received an i.p injection of an equal volume of 0.9% normal saline. Mice received an injection of GSK1120212 (1 mg/kg i.p.) or vehicle control 1 hour before administration of LPS. Mice were euthanized at 18 hr after LPS exposure, and kidneys and blood were collected for analysis. Experiments with TLR4KO mice were graciously donated by Dr. Kenneth D. Chavin and generated by crossing C57BL/10ScN mice with the tlr4LPS-d mutation onto the C57BL/6 background for at least five generations (Ellett et al., 2009; Smith et al., 2015). All studies were conducted in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal use was approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina.

**Serum Creatinine Measurement.** Blood was collected by retro-orbital bleeding puncture and allowed to sit at room temperature for 30 minutes. The samples were centrifuged at 10,000 rpm for 10 min to separate the serum. Serum creatinine (SCr) was determined using the Creatinine Enzymatic Reagent Assay kit (Pointe Scientific, Canton, MI) [c7548-120] based on the manufacturer’s directions. All values are expressed as serum creatinine concentration in milligrams per deciliter.

**RT-qPCR Analysis of mRNA Expression.** Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse Actin RNA and rabbit tubulin RNA were used as
reference genes for normalization. KIM-1 primer sequences used were Fwd- 5’-GCATCTCTAAGCGTGGTTGC-3’ and Rev- 5’-TCAGCTCGGAATGCACAA-3’.

Immunoblot Analysis. Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium orthovanadate (Sigma-Aldrich).

Mouse tissue nuclear and cytosolic fraction lysates were prepared as previously described (24096033, 27875304). Briefly, a piece of kidney cortex was homogenized in sucrose isolation (ISO) buffer (250 mM sucrose, 1 mM EGTA, 10 mM HEPES, 1 mg/ml fatty acid-free BSA [pH 7.4]) added fresh, with a dounce tissue grinder. Lysates were centrifuged at 1000 x g for 10 min. The 1st pellet was pushed through 25G needle 3 times and re-washed three separate times in ISO buffer and resuspended in RIPA. The 1st supernatant was centrifuged at 10,000 x g for 5 min for further purification of the cytosol fraction. Histone H3 and/or Lamin B1 were used as loading control for nuclear lysate immunoblots, and alpha-tubulin was used for loading control of cytosolic lysates.

Equal protein quantities (10–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved by gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and incubated overnight with primary antibody at 4°C with gently agitation. Primary antibodies used in these studies included phospho-ERK1/2 (1:1000) [#4370], total ERK1/2 (1:1000) [#4695], phospho-Chk1 (1:1000) [#12302], Chk1 (1:1000) [#2360], phospho-STAT3-Tyr705 (1:1000) [#9145], phospho-STAT3-Ser727 (1:1000) [#94994], total STAT3 (1:1000) [#9139], Histone H3 (1:2000) [#9715] all from Cell Signaling Technology, Danvers, MA. lamin B1 (1:1000; Abcam) [ab16048], phospho-Chk1 (1:800) [AF2054], kidney injury molecule-1 (KIM-1) (1:1000) [AF1817] from R&D systems, Minneapolis, MN. β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [ sc-47778].
Membranes were incubated with the appropriate horseradish peroxidase–conjugated secondary antibody before visualization using enhanced chemiluminescence (Thermo Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was determined using the ImageJ software from NIH and Image Studio Lite from LI-COR.

**Statistical Analysis.** All data are shown as mean ± S.E.M. When comparing two experimental groups, an unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for comparisons of multiple groups. P < 0.05 was considered statistically significant. All statistical tests were performed using GraphPad Prism software (GraphPad Software, San Diego, CA).
Results

ERK1/2 Increases KIM-1 mRNA Following Toxicant Exposure in Mouse Renal Cells. To confirm KIM-1 expression is upregulated following toxicant exposure, cultured transgenic mouse kidney proximal tubule (TK) cells were treated with 1 and 10 mM hydroxyurea (HU), 0.1 and 1 mM hydrogen peroxide (H₂O₂), and 350 and 700 µM tert-butyl hydroperoxide (TBHP) for 24 hours. HU causes cellular injury by inhibiting DNA synthesis and causing DNA damage (Singh and Xu, 2016), while H₂O₂ and TBHP are model oxidants that lead to oxidative stress causing protein, lipid, and DNA damage (Nowak et al., 2006). Each toxicant increased KIM-1 mRNA with increasing concentration (Fig. 1A). KIM-1 mRNA increased 8-, 3-, and 3-fold in response to 10 mM HU, 1 mM H₂O₂, and 700 µM TBHP, respectively (Fig. 1A). A 1 hr pretreatment with trametinib prevented HU, H₂O₂, and TBHP induced KIM-1 mRNA increases (Fig. 1B). Interestingly, TK cells treated with trametinib alone showed a 54% decrease in KIM-1 mRNA compared to vehicle control cells at 24 hr (Fig. 1B). These data reveal a regulatory role for ERK1/2 on KIM-1 mRNA under control conditions and following DNA and oxidative damage.

Early ERK1/2 Activation Mediates STAT3 Phosphorylation Induced KIM-1 mRNA Upregulation Following IR AKI. KIM-1 mRNA increased 4.7-fold 3 hr post IR AKI compared to sham controls (Fig. 2A). Trametinib attenuated the KIM-1 mRNA and serum creatinine increases when administered 1 hour before IR surgery (Fig. 2A, 2B). The phosphorylated ERK1/2 to total ERK1/2 ratio increased 4.5-fold in the IR groups compared to sham (Fig. 2C, 2D). Trametinib also completely inhibited ERK1/2 phosphorylation increases following AKI, as observed previously (Smith et al., 2015; Collier et al., 2016).

Ajay et al. (2014) reported that Chk1 phosphorylation is elevated 3 hr post IR AKI. In contrast, we did not observe any change in phosphorylated Chk1 to total Chk1 ratio following IR injury in the presence or absence of trametinib. However, transcription factor STAT3 phosphorylation at both activating sites, S727 and Y705, increased 2.5- and 3.5-fold after renal IR, respectively (Fig. 2C, 2E-H) and
pretreatment with trametinib partially blocked the increase in phosphorylation of STAT3 at S727 and Y705 (Fig. 2G, 2H). These findings suggest that inhibiting ERK1/2 phosphorylation prevents KIM-1 mRNA upregulation 3 hr post IR AKI by preventing STAT3 phosphorylation at S727 and Y705.

**ERK1/2 Inhibition Suppresses KIM-1 mRNA and Protein 24 hr Following IR AKI.** At 24 hr, KIM-1 mRNA was ~280-fold higher in the IR group compared to sham controls (Fig. 3A). Trametinib partially blocked the increase in KIM-1 mRNA (~120-fold higher compared to sham) compared to the IR mice (Fig. 3A). Serum creatinine increased to 1.1 mg/dL in the IR group and pretreatment with trametinib attenuated this rise in serum creatinine at 24 hr (Fig. 3B). STAT3 phosphorylation at S727 and Y705 increased following renal IR injury and trametinib pretreatment blocked these increases (Fig. 3D, 3G-H). Chk1 phosphorylation decreased in the IR group at 24 hr and ERK1/2 inhibition had no influence on Chk1 phosphorylation (Fig. 3D, 3F). Trametinib inhibited ERK1/2 phosphorylation throughout the 24 hr period after IR surgery (Fig. 3D, 3E). The IR group showed a large upregulation in KIM-1 kidney cortex protein that was markedly reduced in the presence of trametinib at 24 hr (Fig. 3C). Because KIM-1 is cleaved from the cell surface, KIM-1 protein was measured in the serum to detect any changes in cleavage regulation (Sabbisetti et al., 2014). Serum KIM-1 protein was high in the IR group and was markedly reduced in the trametinib group (Fig. 3C). These findings reveal ERK1/2 remains activated 24 hr following IR AKI, which corresponds to increased phosphorylation of STAT3 at S727 and Y705, and leads to increases in KIM-1 mRNA and protein. This correlates with our observations of STAT3 phosphorylation at S727 and Y705 in the trametinib group compared to the IR group in our 3 hr study (Fig. 2F-H). It is clear, however, that ERK1/2 and STAT3 are not the only pathway responsible for the later increases in KIM-1 mRNA, as the trametinib group is only partially attenuated at 24 hr (Fig. 3A).

**ERK1/2 Increases KIM-1 mRNA in Sepsis Induced AKI and Requires TLR4.** Previously, we demonstrated LPS-induced AKI requires TLR4 mediated ERK1/2 activation at the initiation of injury to impair kidney function through mitochondrial dysfunction and inflammatory cytokines (Smith et al., 2015). Similarly, partial attenuation of KIM-1 mRNA upregulation through ERK1/2 inhibition prior to LPS
administration at 18 hrs was observed (Smith et al., 2015). Here, trametinib treatment prevented KIM-1 protein upregulation within the kidney cortex compared to LPS alone at 18 hr (Fig. 4A). ERK1/2 phosphorylation was inhibited in the trametinib + LPS group compared to the control and LPS group, whereas the LPS group was not different from controls (Fig. 4A, 4B). To further illustrate pharmacological ERK1/2 inhibition downregulates KIM-1 expression, ERK1/2 phosphorylation was studied following LPS in TLR4KO mice, as TLR4 is required for LPS-induced kidney dysfunction (Smith et al., 2015). TLR4KO mice had reduced ERK1/2 phosphorylation compared to WT mice administered LPS (Fig. 4D, 4F). LPS induced increases in KIM-1 mRNA and KIM-1 protein were attenuated in LPS treated TLR4KO mice, connecting ERK1/2 activation and KIM-1 to TLR4 (Fig. 4D, 4E). For confirmation, TLR4 mRNA expression in the TLR4KO mice was negligible compared to WT TLR4 mRNA expression (Fig. 4C).

**TLR4 is Not Required for IR-Induced ERK1/2 Phosphorylation and KIM-1 mRNA Upregulation.**

To determine if ERK1/2 and KIM-1 are regulated by TLR4 during initiation of injury following IR AKI, TLR4KO mice were subjected to IR surgeries and KIM-1 alterations were observed at 3 hr. The WT and TLR4KO mice had similar increases in phosphorylated ERK1/2 following IR AKI compared to their sham controls (Fig. 5A, 5C). Interestingly, KIM-1 mRNA was markedly elevated in the TLR4KO IR mice and WT IR mice trended upward (Fig. 5B). The above findings demonstrate that IR AKI induced KIM-1 upregulation and ERK1/2 activation are TLR4 independent.

**ERK1/2 Inhibition Decreases KIM-1 mRNA, and Nuclear and Cytosolic STAT3 Phosphorylation Under Physiological Conditions.** To determine if ERK1/2 regulates KIM-1 at a physiological level, naïve mice were treated with trametinib or vehicle for 4 hr. Unexpectedly, trametinib treated mice had ~55% lower KIM-1 mRNA compared to vehicle control mice (Fig. 6A). The trametinib group had reduced ERK1/2 phosphorylation in the nucleus and cytosol (Fig. 6G, 6H). Nuclear STAT3 phosphorylation at sites Y705 and S727 were down in the trametinib group 55% and 46%, respectively, compared to the vehicle control group (Fig. 6B-D). Phosphorylated Y705 and S727 on STAT3 in the
cytosol was also reduced in the trametinib group (Fig. 6E, 6F). To confirm that trametinib was inhibiting nuclear STAT3 phosphorylation, and subsequently KIM-1 mRNA downregulation, cytosol and nuclear fractions were isolated and confirmed for purity using α-tubulin and lamin B1 (Fig. 6H). The purified fractions demonstrated that inhibition of physiological ERK1/2 phosphorylation results in a decrease in KIM-1 mRNA through reducing STAT3 phosphorylation at Y705 and S727 in the kidney. By decreasing active STAT3 within the nucleus there is potential for less KIM-1 promoter binding, resulting in lower KIM-1 mRNA expression.
Discussion

In this study, ERK1/2 was identified as a regulator of KIM-1 expression. ERK1/2 inhibition prevented KIM-1 transcription *in vitro* following toxicant exposure, and attenuated increases in KIM-1 mRNA and protein in IR AKI. STAT3 phosphorylation at S727 and Y705 decreased as a result of ERK1/2 inhibition, leading to less KIM-1 expression. In sepsis-induced AKI, TLR4 was required for activation of ERK1/2 and KIM-1 upregulation. In contrast, ERK1/2 phosphorylation following IR AKI was not dependent on TLR4. Interestingly, in naïve mice ERK1/2 regulates KIM-1 mRNA by physiological STAT3 phosphorylation in the nucleus. We suggest ERK1/2 regulates renal KIM-1 expression at a physiological level and initially during pathological renal injury by phosphorylation of STAT3.

The discovery that KIM-1 is the most upregulated gene following AKI led to an increase in KIM-1 renal research (Ichimura et al., 1998; Vaidya et al., 2006; Vaidya et al., 2010). Ajay et al. explored the signaling pathway that results in upregulation of renal KIM-1 transcription. They reported KIM-1 transcriptional regulation by Chk1-STAT3 interaction following AKI-induced DNA damage. Chk1 was revealed as an upstream kinase of STAT3 and phosphorylation at S727 and Y705 on STAT3 was required for KIM-1 upregulation (Ajay et al., 2014). Phosphorylated STAT3 increased following AKI and was found to bind to the KIM-1 promoter, therefore increasing KIM-1 mRNA and protein (Ajay et al., 2014). While our studies support the work of Ajay et al., important differences were observed. (1) Chk1 phosphorylation did not increase following IR AKI at 3 and 24 hr. (2) ERK1/2 was responsible for the STAT3 phosphorylation after IR. (3) Our IR experimental design utilized mice rather than rats for AKI. Chk1 phosphorylation did not increase in the renal cortex in our experiments, yet, KIM-1 mRNA and renal dysfunction was observed. Nevertheless, STAT3 phosphorylation was verified to increase following renal injury, and a reduction in phosphorylated STAT3 attenuated KIM-1 mRNA. However, ERK1/2 was demonstrated as the key initial regulator of STAT3 phosphorylation following renal injury, rather than Chk1.
We previously published work demonstrating that inhibiting the rapid activation of ERK1/2 following renal injury prevents and/or attenuates injury and dysfunction through restoration of mitochondrial function, renal microvascular perfusion, and attenuation of pro-inflammatory cytokines (Smith et al., 2015; Collier et al., 2016; Smith et al., 2016). Here, ERK1/2 involvement with STAT3 after renal injury was observed. STAT3 phosphorylation is activated early in tubule cells following injury, although the exact role in kidney dysfunction and recovery varies in different AKI models (Talbot et al., 2011; Brosius and He, 2015). For example, in HgCl₂, IR, and aristolochic acid induced AKI, early STAT3 phosphorylation was protective (Nechemia-Arbely et al., 2008; Zhou et al., 2010). In contrast, inhibition of STAT3 phosphorylation in polycystic kidney disease, unilateral ureteral obstruction, and HIV-associated nephropathy has shown beneficial outcomes (Pang et al., 2010; Takakura et al., 2011; Gu et al., 2013). Our findings suggest that prevention of renal IR-induced STAT3 phosphorylation through ERK1/2 inhibition attenuates serum creatinine and KIM-1 expression.

Previous experiments demonstrated activated ERK1/2 phosphorylates STAT3 at S727, while at the same time decreasing STAT3 Y705 phosphorylation (Booz et al., 2003; Kanai et al., 2003; Gough et al., 2013). However, in our study both S727 and Y705 phosphorylation increased following IR injury and decreased with pretreatment with trametinib, suggesting ERK1/2 is responsible for phosphorylating both sites. At 24 hr following IR AKI, a partial reduction of KIM-1 mRNA in the trametinib group was observed, along with a complete attenuation of serum creatinine elevation compared to the IR group. KIM-1 protein levels were substantially lower in the trametinib treated mice, both in the kidney cortex and in the circulatory system, as KIM-1 can be detected in the blood. This occurrence has been recognized due to the loss of cell polarity, microvascular permeability dysfunction, disruption of cell-cell adhesion junctions, and basement membrane cell detachment (Sabbisetti et al., 2014; Tian et al., 2017).

ERK1/2 phosphorylation was found to regulate KIM-1 expression in a second AKI model. LPS-induced AKI increased ERK1/2 phosphorylation and KIM-1 protein, whereas trametinib prevented ERK1/2
activation and attenuated the KIM-1 protein increase. Further characterization of the ERK1/2-KIM-1 pathway was demonstrated by utilization of TLR4KO mice. TLR4 is required for LPS-induced ERK1/2 phosphorylation and subsequently, KIM-1 mRNA upregulation (Smith et al., 2015). ERK1/2 is rapidly phosphorylated following LPS at 1 and 3 hr, however in this study, at 18 hr post-LPS phosphorylated ERK1/2 was not different than the control group, most likely stemming from a prompt compensatory mechanism. Nonetheless, 18 hr after CLP, which is a slower developing sepsis model, ERK1/2 phosphorylation is still highly phosphorylated compared to controls (Smith et al., 2015; Smith et al., 2016). To verify that TLR4 signaling was not regulating KIM-1 expression directly, the TLR4KO mice underwent IR AKI and were compared to the wild type mice. There were no differences in ERK1/2 phosphorylation between the TLR4KO IR group and the WT IR group, and the TLR4KO group had increased KIM-1 mRNA. Thus, TLR4 is required for LPS induced ERK1/2 activation and increase in KIM-1 mRNA, yet in IR AKI TLR4 is not required since ERK1/2 is activated via other non-TLR4 upstream pathways. Therefore, we view ERK1/2 phosphorylation as a key event controlling KIM-1 regulation, and is activated through different pathways in different diseases.

To determine if ERK1/2 regulated KIM-1 at a physiological level, trametinib was administered to naïve mice. Although KIM-1 is expressed at very low levels in healthy non-injured kidneys, there is a physiological basal level of detection (Ichimura et al., 1998; van Timmeren et al., 2006). In the absence of an injury, inhibiting physiological ERK1/2 phosphorylation resulted in the downregulation of KIM-1 mRNA. This observation correlates with our in vitro results that demonstrated trametinib treatment in mouse TK cells decreased KIM-1 mRNA. Phosphorylated Chk1 was not altered in the trametinib treated mice (data not shown). ERK1/2 phosphorylation was inhibited in the nuclear and cytosolic fractions of the kidney cortex, which decreased STAT3 Y705 and S727 phosphorylation in the nucleus. Therefore, less active STAT3 is able to bind to the KIM-1 promoter, corresponding to the KIM-1 mRNA reduction observed.
We have provided evidence that STAT3 phosphorylated at Y705 and S727 are partially responsible for renal KIM-1 upregulation, and that ERK1/2 involvement is upstream of STAT3. These findings provide further evidence that initial ERK1/2 activation is a key regulator of various pathways following renal injury, which may lead to the discovery of potential pharmacological based therapies.
Acknowledgements
Authorship Contributions

Participated in research design: Collier, Schnellmann.

Conducted experiments: Collier.

Performed data analysis: Collier.

Wrote or contributed to the writing of the manuscript: Collier, Schnellmann.
References


This article has not been copyedited and formatted. The final version may differ from this version.
Footnotes

This study was funded by National Institutes of Health National Institute of General Medical Sciences [R01GM084147] award to R.G.S.; the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [BX000851] awarded to R.G.S.; and the Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship through the National Institute of Diabetes and Digestive and Kidney Diseases [F31DK105782] awarded to J.B.C.
Figure Legends

Fig. 1. ERK1/2 increases KIM-1 mRNA after toxicant exposure in mouse TK cells. (A) KIM-1 mRNA expression at 24 hr following exposure to HU, H₂O₂, and TBHP. (B) KIM-1 mRNA measured at 24 hr post toxicant administration with or without 1 hr trametinib (GSK) pre-treatment. Data are represented as mean ± SEM, n ≥ 4. Superscripts indicate statistically significant differences (P < 0.05).* Significantly different than vehicle control. # Significance between same toxicant groups.

Fig. 2. ERK1/2 mediates STAT3 phosphorylation and KIM-1 mRNA upregulation following 3 hr of IR AKI. (A) KIM-1 mRNA expression following IR AKI at 3 hr. (B) Serum creatinine was assessed 3 hr after IR AKI. (C) Representative immunoblot of phosphorylated ERK1/2, total ERK1/2, phosphorylated Chk1, and total Chk1 following 3hr IR AKI. (D) Densitometry analysis of phosphorylated ERK1/2 compared to total ERK1/2. (E) Densitometry analysis of phosphorylated Chk1 compared to total Chk1. (F) Representative immunoblot of phosphorylated STAT3 (S727 and Y705) and total STAT3 following 3 hr IR AKI. (G, H) Densitometry analysis of phosphorylated STAT3 (S727 and Y705) compared to total STAT3. Data are represented as mean ± SEM, n = 6. Different superscripts indicate statistically significant differences (P < 0.05).

Fig. 3. ERK1/2 mediates KIM-1 mRNA and protein increases and STAT3 phosphorylation following 24 hr of IR AKI. (A) KIM-1 mRNA expression following IR AKI at 24 hr. (B) Serum creatinine was assessed 24 hr after IR AKI. (C) Representative immunoblot of renal KIM-1 and serum KIM-1 (n = 2 in IR group) following 24 hr IR AKI. (D) Representative immunoblot of phosphorylated ERK1/2, total ERK1/2, phosphorylated STAT3 (S727 and Y705), total STAT3, phosphorylated Chk1, and total Chk1 following IR AKI. (E-H) Densitometry analysis of phosphorylated (E) ERK1/2 to total ERK1/2; (F) p-Chk1 to total Chk1; (G) p-STAT3 S727 to total STAT3; (H) p-STAT3 Y705 to total STAT3. Data are represented as mean ± SEM, n ≥ 5, except where indicated. Different superscripts indicate statistically significant differences (P < 0.05).
Fig. 4. ERK1/2 increases KIM-1 mRNA and protein in LPS-induced AKI through TLR4 at 18 hr. (A) Representative immunoblot of KIM-1, phosphorylated ERK1/2, and total ERK1/2 following LPS-induced AKI. (B) Densitometry analysis of phosphorylated ERK1/2 compared to total ERK1/2. (C) TLR4 mRNA measured in WT mice kidney and TLR4KO mice kidney. (D) Representative immunoblot of KIM-1, phosphorylated ERK1/2, and total ERK1/2 following LPS-induced AKI in WT and TLR4KO mice. (E) KIM-1 mRNA measured in WT mice kidney and TLR4KO mice kidney following LPS-induced AKI at 18 hr. (F) Densitometry analysis of renal phosphorylated ERK1/2 compared to total ERK1/2 in the LPS treated WT and TLR4KO mice. Data are represented as mean ± SEM, n ≥ 3. Different superscripts indicate statistically significant differences (P < 0.05).

Fig. 5. TLR4 is not required for IR-induced ERK1/2 phosphorylation and KIM-1 mRNA upregulation. (A) Representative immunoblot of phosphorylated ERK1/2 and total ERK1/2 following IR-induced AKI at 3 hr in WT and TLR4KO mice. (B) KIM-1 mRNA measured in WT mice kidney and TLR4KO mice kidney following IR-induced AKI at 3 hr. (C) Densitometry analysis of renal phosphorylated ERK1/2 compared to total ERK1/2 in the WT and TLR4KO mice following IR-induced AKI. Data are represented as mean ± SEM, n ≥ 3. Different superscripts indicate statistically significant differences (P < 0.05).

Fig. 6. ERK1/2 inhibition decreases KIM-1 mRNA, and nuclear and cytosolic STAT3 phosphorylation under physiological conditions in naïve mice. (A) Representative immunoblot of nuclear phosphorylated STAT3 (S727 and Y705) and total STAT3 in naïve mice after 4 hr treatment with trametinib. (B) KIM-1 mRNA measured at 4 hr post trametinib treatment. (C, D) Densitometry analysis of nuclear phosphorylated STAT3 (S727 and Y705) compared to total STAT3. (E) Representative immunoblot of cytosol phosphorylated STAT3 (S727 and Y705) and total STAT3 in naïve mice after 4 hr treatment with trametinib. (F) Densitometry analysis of cytosol phosphorylated STAT3 (S727 and Y705) compared to total STAT3. (G) Densitometry analysis of nuclear and cytosol phosphorylated ERK1/2 compared to total ERK1/2. (H) Representative and verification renal immunoblot of nuclear and cytosol...
control proteins with and without trametinib treatment. Data are represented as mean ± SEM, n ≥ 6.

Different superscripts indicate statistically significant differences (P < 0.05).
Figure 1

(A) KIM1 mRNA expression following various treatments.

(B) Trametinib pretreatment effects on KIM1 mRNA expression.
Figure 2
Figure 4.
Figure 5.
Figure 6.

A. KIM1 mRNA

B. Nuclear

C. Nuclear p-STAT3 (S727)

D. Nuclear p-STAT3 (Y705)

E. Cytosol

F. Cytosol p-STAT3

G. pERK1/2

H. Nuclear

I. Cytosol

This article has not been copyedited and formatted. The final version may differ from this version.